Billie-Jo (BJ) Kerns joined High Throughput Genomics Inc. (HTG) as vice president, Strategic Marketing and Business Development, in March 2008. In this position, BJ is responsible for developing and implementing HTG's strategic plan and business development activities. A significant area of her responsibility is managing HTG's emerging diagnostics business, specifically overseeing the development of the diagnostic content for the qNPA system.
Most recently, BJ held the position of director of Integrated Solutions and Molecular Diagnostics at Promega Corp. Inc. Previously, she held several positions at Ventana Medical Systems Inc., including director of Women's Health, director of Strategic Marketing, and senior director of Product Technical Support in Operations. BJ has also managed a variety of functions at BioGenex and Becton Dickinson, including business development, sales and marketing, research and development, and project management.
BJ brings with her more than 27 years of diagnostics experience, including launching Ventana Medical Systems' first FDA-approved companion diagnostic, PATHWAY® HER-2. She has an academic background in science and medicine, which augments her general management, sales, marketing, and business development skills. While at Duke University Medical Center, BJ published 60 scientific papers and 38 abstracts, and she has presented over 30 workshops in her career to date.
BJ received an AAS in Medical Technology from Elon College in Elon, North Carolina, and a BS in Health Care Management from Century University in Albuquerque, New Mexico. She has received a certification in Managing Strategic Resources from Darden Executive Education at the University of Virginia.